Enwei Pharmaceutical Co., Ltd. (SHE:301331)
China flag China · Delayed Price · Currency is CNY
23.98
+0.19 (0.80%)
At close: Nov 13, 2026

Enwei Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
37.7851.9437.586.3167.8101.73
Depreciation & Amortization
47.4747.4746.4834.8330.9130.5
Other Amortization
4.824.826.236.556.885.59
Loss (Gain) From Sale of Assets
0.140.140.260.04--
Asset Writedown & Restructuring Costs
4.424.425.440.581.650.07
Loss (Gain) From Sale of Investments
-5.2-5.2-3.49-3.74-0.590.44
Other Operating Activities
29.856.123.840.35-1.56-0.52
Change in Accounts Receivable
-21.12-21.12-36.43-9.67-69.8930.16
Change in Inventory
16.4316.43-12.06-2.95.4-31.39
Change in Accounts Payable
3.163.1612.96-27.8122.12-50.73
Operating Cash Flow
119.19109.5978.9284.0162.3587.58
Operating Cash Flow Growth
42.47%38.87%-6.06%34.73%-28.80%11.53%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-51.69-56.38-50.23-134.05-23.56-38.21
Sale of Property, Plant & Equipment
2.950.040.340.15--
Cash Acquisitions
-0.07-0.07----
Investment in Securities
-1,703-1,694-1,018-685.5-221.5-
Other Investing Activities
1,7371,671957.37775.221.050.52
Investing Cash Flow
-14.21-78.83-110.62-44.18-244.01-37.7

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
--241.8---
Long-Term Debt Repaid
--11.69-48.09---
Lease Payments
-1.69-1.69-1.29---
Net Debt Issued (Repaid)
9.28-11.69193.71---
Issuance of Common Stock
10.7710.7718.36-470.75-
Repurchase of Common Stock
---70.01-33--
Common Dividends Paid
-106.95-20.78-56.96-112.22--46
Other Financing Activities
-1.16----12.28-2.41
Financing Cash Flow
-88.05-21.6985.1-145.22458.47-48.41

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-0-00-0.030.16-0.24
Net Cash Flow
16.939.0853.41-105.41276.981.23

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
67.553.2128.69-50.0438.849.36
Free Cash Flow Growth
105.27%85.50%---21.41%4.24%
Free Cash Flow Margin
8.14%5.91%3.53%-6.37%5.61%7.26%
Free Cash Flow Per Share
0.640.520.28-0.490.460.63
Levered Free Cash Flow
53.6774.4626.78-68.8341.2521.46
Unlevered Free Cash Flow
54.9476.0628.29-68.8341.2521.46
Free Cash Flow After Leases
65.8251.5327.39-50.0438.849.36

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
66.3276.3680.8784.8658.9379.2
Change in Working Capital
-0.1-0.1-37.33-40.9-42.73-50.23